NEW YORK (GenomeWeb News) – Thermo Fisher Scientific priced the $2.2 billion public offering of its stock at $85.50 per share. The company will offer about 25.7 million shares of its stock in connection to the offering, and proceeds will be used to fund, in part, its $13.6 billion acquisition of Life Technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.